Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbalife acquisition

This article was originally published in The Tan Sheet

Executive Summary

Direct marketer cancels Euro tranche of high-yield bond due to lack of demand in Europe, company says. Proceeds were to be used toward financing of going-private transaction, which is still expected to close this summer. Firm previously planned to use up to $238 mil. in net proceeds from issuance of senior subordinated notes offered in Euro, U.S. dollar-denominated tranches (1"The Tan Sheet" June 17, 2002, p. 5). In revised filing with SEC June 27, Herbalife now says it will contribute approximately $213.9 mil. in available cash toward the acquisition. Financing also will include $162.9 mil. in proceeds from senior subordinated notes, up to $24.8 mil. from senior notes. Acquiring companies Whitney, Golden Gate now expected to provide equity financing of $176 mil., although amount could increase to $220.3 mil...

You may also be interested in...

Herbalife Ephedrine Alkaloid Supplements Slated For Discontinuation

Herbalife is getting out of the ephedra supplement business

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts